Enliven Therapeutics (ELVN) Other financing activities (2020 - 2026)

Enliven Therapeutics (ELVN) has 7 years of Other financing activities data on file, last reported at $10.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities rose 4196.15% year-over-year to $10.1 million; the trailing twelve-month figure through Mar 2026 stood at $12.1 million (up 236.97% YoY), and the FY2025 full-year result was $2.3 million, down 36.79% from the prior year.
• Other financing activities improved to $10.1 million in Q1 2026, from $528000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $10.1 million in Q1 2026 to a low of $5000.0 in Q2 2022.
• A 5-year average of $1.1 million and a median of $252000.0 in 2024 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities tumbled 97.94% in 2022 and surged 4196.15% in 2026, its largest moves.
• Tracing ELVN's Other financing activities over 5 years: stood at $13000.0 in 2022, then jumped by 592.31% to $90000.0 in 2023, then jumped by 403.33% to $453000.0 in 2024, then grew by 16.56% to $528000.0 in 2025, then jumped by 1803.98% to $10.1 million in 2026.
• Business Quant data shows ELVN's Other financing activities at $10.1 million in Q1 2026, $528000.0 in Q4 2025, and $209000.0 in Q3 2025.